Loading...
XSHE
300584
Market cap594mUSD
Jul 09, Last price  
33.60CNY
1D
-1.35%
1Q
-23.43%
IPO
186.36%
Name

Nanjing Hicin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300584 chart
P/E
95.87
P/S
6.01
EPS
0.35
Div Yield, %
0.30%
Shrs. gr., 5y
Rev. gr., 5y
3.02%
Revenues
671m
+33.05%
147,952,995169,502,080197,655,206220,993,472280,827,570455,034,584711,907,832924,537,939706,295,709578,315,038578,315,038526,465,340526,465,339517,832,190504,360,393671,048,953
Net income
42m
+4.58%
25,592,00933,287,34334,214,07840,328,96345,236,37865,600,50683,223,21797,258,21355,230,056285,878,182285,878,18932,448,86732,448,87036,315,55840,217,91342,058,385
CFO
78m
+30.24%
38,767,53845,164,66524,293,22753,902,47537,737,79046,557,48177,210,75497,277,03973,388,59359,940,771023,932,69259,960,14178,089,132
Dividend
Jun 09, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nanjing Hicin Pharmaceutical Co., Ltd. (NHPC), established in 2003 and headquartered in Nanjing, China, operates as a comprehensive enterprise specializing in the research, development, production, marketing, and distribution of pharmaceutical preparations and synthetic chemicals within China. The company boasts a diverse product portfolio, addressing various therapeutic areas such as antivirals, antibiotics, endocrine regulators, gastrointestinal treatments, orthopedic medications, cardiovascular and cerebrovascular drugs, and immunomodulatory agents. Beyond its core pharmaceutical activities, NHPC also provides technology transfer services. On an international scale, Nanjing Hicin Pharmaceutical Co., Ltd. is a supplier of Active Pharmaceutical Ingredients (APIs). Its export offerings specifically include injectable forms of omeprazole sodium and cefepime hydrochloride, along with lansoprazole tablets, which reach markets across South Asia, South America, and Europe.
IPO date
Jan 12, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT